4 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
4 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma]
25 MG/ML · Injection · injection
A form of bevacizumab-adcd →
4 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma] — VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors. Strength, form, class, interactions & more.
![4 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe&name=vegzelma-01.jpg)
Active ingredient
Classification
VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsVascular Endothelial Growth Factor Inhibitor
Drug interactions
Bevacizumab does not significantly affect the pharmacokinetics of certain drugs, but there may be reduced exposure to paclitaxel when combined with carboplatin and bevacizumab.
- moderatepaclitaxel — lower paclitaxel exposure after treatment
- moderatecarboplatin — lower paclitaxel exposure after treatment
- unknownirinotecan — no clinically meaningful effect on pharmacokinetics
- unknowninterferon alfa — no clinically meaningful effect on pharmacokinetics
- unknowncarboplatin — no clinically meaningful effect on pharmacokinetics
- unknownpaclitaxel — no clinically meaningful effect on pharmacokinetics
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication